Feedback
Settings

Settings

Goto Application

11,532 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(DWRXFEITVBNRMK-JXOAFFINSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 1,154
1.WO/2026/018181IMMUNOGENIC COMPOSITIONS AND USES THEREOF
WO - 22.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2025/057203 Applicant PFIZER INC. Inventor HUANG, Bridget Yih Jiin
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
2.WO/2026/019998VACCINES FOR KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS
WO - 22.01.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/038046 Applicant THE CLEVELAND CLINIC FOUNDATION Inventor JUNG, Jae
Provided herein are compositions, systems, kits, and methods for immunizing a subject against Kaposi's sarcoma-associated herpesvirus (KSHV) with a composition: i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: KSHV K8.1 protein, or ii) polynucleotides encoding said fusion proteins (e.g., human codon optimized mRNA sequences present in lipid nanoparticles). In other embodiments, provided herein are compositions, systems, and kits, and methods for immunizing a subject against KSHV employing a human codon optimized nucleic acid sequence (e.g., mRNA) encoding a KSHV K8.1 protein.
3.WO/2026/017917RNAS WITH REDUCED RIBOSOMAL FRAMESHIFT EXPRESSION PRODUCTS
WO - 22.01.2026
Int.Class A61K 31/7115
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
 Appl.No PCT/EP2025/070923 Applicant ETHRIS GMBH Inventor BEGUIN, Estelle
The present invention relates to RNAs and compositions comprising said RNAs designed for reducing or avoiding ribosomal frameshift mutations. More particularly, the invention pertains to therapeutic compositions that essentially do not exhibit ribosomal frameshift mutation. These compositions include specific carriers and therapeutic agents suitable for various medical applications.
4.WO/2026/015937NOVEL TREATMENT FOR DIABETES AND OBESITY
WO - 22.01.2026
Int.Class A61K 38/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
 Appl.No PCT/AU2025/050761 Applicant THE UNIVERSITY OF MELBOURNE Inventor EKINCI, Elif Ilhan
The present invention relates to compositions for the prevention or treatment of a metabolic disorder. In one aspect, the invention relates to the regulation of blood glucose levels and/or lipid metabolism with a composition of the invention.
5.WO/2026/020002ENHANCING NEURONAL RESISTANCE TO NEURODEGENERATION
WO - 22.01.2026
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/US2025/038051 Applicant NEW YORK UNIVERSITY Inventor NGUYEN, Hoa, Quang, My
The application relates to methods of enhancing neuronal resistance to disease characterized by TAR DNA-binding protein 43 (TDP-43) mislocalization or dysfunction, e.g., a neurodegenerative disease.
6.WO/2026/019692IMMUNOMODULATORY FUSION PROTEINS AND RELATED METHODS
WO - 22.01.2026
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
 Appl.No PCT/US2025/037499 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor BANDUKWALA, Hozefa Saifuddin
Provided herein are immunomodulatory fusion proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunomodulatory fusion proteins and compositions. The immunomodulatory fusion proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., methods of suppressing or reducing (e.g., preventing) a pro-inflammatory immune response in a subject).
7.WO/2026/015829SMALL REVERSE TRANSCRIPTASES AND GENE EDITING SYSTEMS COMPRISING SUCH
WO - 15.01.2026
Int.Class C12N 9/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
12transferring phosphorus containing groups, e.g. kinases (2.7)
 Appl.No PCT/US2025/037333 Applicant ARBOR BIOTECHNOLOGIES, INC. Inventor LAPAN, André P.
Small-sized reverse transcriptase (RT) polypeptides derived from SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 and fusion polypeptides comprising such an RT polypeptide and an RNA-guided nucleases. Also provided herein are gene editing systems comprising the RT polypeptide, the RNA-guided nucleases, a guide RNA, and an RT donor RNA for use in gene editing.
8.WO/2026/013624DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
WO - 15.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/IB2025/057021 Applicant NOVARTIS AG Inventor HUNZIKER, Juerg
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), for example, human HMGCR, compositions including the same, and methods of treatment using the same.
9.WO/2026/014855FUSION PROTEIN COMPRISING APOLIPOPROTEIN AND FC REGION-BINDING PEPTIDE AND USES THEREOF
WO - 15.01.2026
Int.Class C07K 14/775
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
775Apolipopeptides
 Appl.No PCT/KR2025/009774 Applicant RNAGENE INC. Inventor LEE, Woo Ghil
The present invention relates to a fusion protein and a use thereof, wherein the fusion protein comprises: an apolipoprotein or a fragment thereof; and an Fc-binding peptide (Fc BP) or a fragment thereof. According to one aspect, a lipid carrier comprising the fusion protein was found to exhibit remarkably improved targeting efficiency, and thus can be used to deliver an active substance to a desired target.
10.WO/2026/013176ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
WO - 15.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/069685 Applicant PROQR THERAPEUTICS II B.V. Inventor HOLKERS, Maarten
The disclosure relates to the field of diseases caused by high levels of LDL-C and/or fibrinogen, such as cardiovascular disease (CVD). The disclosure involves antisense oligonucleotides (AONs) for RNA editing technology in deaminating a specific adenosine in transcript molecules of the human Asparagine-Linked Glycosylation 12 homolog glycosyltransferase (ALG12) gene, thereby rendering a mutation from a serine residue at position 275 in the human ALG12 amino acid sequence to a glycine residue (S275G).
# -